
Visible Genomics, a Chicago-area genetics testing company, announced Sept. 14 that it had launched a non-invasive genetic eye test that determines a patient’s likelihood of contracting age-related macular degeneration (AMD).
Visible Genomics said up to 70 percent of AMD cases can be linked to multiple genetic variants. Its test is recommended for people who have a family history of the disease, or those showing signs of early or intermediate AMD.
The company said its clinically validated saliva-based test combines a person’s genetic factors, ocular findings, and demographic and lifestyle characteristics into a comprehensive and clinically actionable risk assessment.